Innate Immune Agonists in Cancer Immunotherapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 4121
Special Issue Editor
Special Issue Information
Dear Colleagues,
There is a pressing need to overcome the low immunogenicity of cancer vaccines as well as to lower the tumor microenvironment’s tolerance. Pathogen-associated molecular patterns (PAMPs) delivered into tumors make them look like pathogen-infected tissues and elicit an innate immune activation cascade to lower this tolerance. Our immune cells contain a series of pattern recognition receptors (PRRs), activated by PAMPs as well as small molecule innate immune agonists, which structurally resemble PAMPs but lack their infectious capacities. These agonists engage the immune cells via the induction of inflammatory cytokines, interferons, and co-stimulatory molecules and provide indispensable initial signals that determine the type, magnitude, and durability of the immune response. Several small molecule PRR agonists have been developed and actively pursued for their antitumor potential, either as immunotherapeutics or vaccine adjuvants. This Special Issue aims to highlight the use of innate immune agonists in cancer immunotherapy as an approach that has enormous, yet somehow still untapped, potential to induce antitumor immunity.
Dr. Žiga Jakopin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NOD agonists
- TLR agonists
- STING agonists
- RIG-I agonists
- CLR agonists
- pattern recognition receptors
- cancer immunotherapy
- antitumor
- innate immune agonists
- immunostimulants
